Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
Forde discusses results from the PAPILLON trial (NCT04538664) of amivantamab, a bispecific antibody targeting EGFR and MET in EGFR exon 20 insertion–mutated non–small cell lung cancer (NSCLC). EGFR exon 20 insertions occur in about 2% 3% of NSCLC cases, predominantly nonsquamous histology. Amivantamab is approved in previously treated EGFR exon 20 NSCLC.
The PAPILLON trial compared amivantamab plus chemotherapy with chemotherapy alone in untreated advanced EGFR exon 20 NSCLC. Amivantamab plus chemotherapy significantly improved progression-free survival with an HR of 0.395 vs chemotherapy alone. Objective response rate increased from 47% with chemotherapy to 73% with amivantamab plus chemotherapy. There was also an early overall survival trend favoring amivantamab.
Forde states these results support up-front use of amivantamab plus chemotherapy for EGFR exon 20 advanced NSCLC. He notes amivantamab can cause infusion reactions and increased venous thromboembolism risk to monitor. Overall, this regimen meaningfully improves outcomes for patients with this rare EGFR alteration.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.